A remarkable new study from investigators at the National Institutes of Health has uncovered an unexpected mechanism underlying one of chemotherapy’s most debilitating side effects: cisplatin-induced peripheral neuropathy. Rather than DNA repair simply protecting neurons, the researchers found that DNA repair itself can become toxic when neurons lack sufficient deoxynucleotide (dNTP) pools to complete the repair process.

Their work shows that nucleotide excision repair (NER) begins removing cisplatin-induced DNA lesions normally. However, because mature neurons maintain very low intracellular dNTP pools, repair frequently stalls before completion. The result is accumulation of DNA breaks, neuronal death, and ultimately peripheral neuropathy.

The exciting discovery is that replenishing cellular nucleotide pools—either by supplying deoxynucleosides or genetically increasing intracellular dNTP levels—dramatically improved neuronal survival and reduced neuropathy in animal models.

A broader implication

While this work focused on cisplatin, it raises an intriguing question that extends well beyond platinum chemotherapy.

Many anti-cancer agents—including topoisomerase poisons—produce DNA lesions that must also be repaired by the cell. Could insufficient nucleotide pools similarly limit repair in vulnerable post-mitotic tissues such as:

• peripheral neurons
• cardiac muscle
• cochlear cells
• other non-dividing tissues

If so, transient enhancement of nucleotide availability might reduce treatment-associated toxicity while preserving anti-tumor efficacy.

Where TopoGEN fits

These questions require robust methods to measure DNA damage, repair, and drug mechanism.

TopoGEN’s portfolio—including ICE® Assays, purified human topoisomerases, DNA repair reagents, and mechanistic drug screening platforms—provides researchers with the tools needed to explore precisely these types of questions.

As oncology moves toward maximizing efficacy while minimizing toxicity, understanding how DNA repair pathways influence collateral tissue damage may become just as important as understanding how drugs kill tumor cells.

This new study represents an exciting step in that direction.